期刊文献+

阿齐沙坦的合成工艺优化

Improved synthetic process of azilsartan
下载PDF
导出
摘要 目的改进阿齐沙坦合成中的硝基还原反应工艺。方法以2-{[(2-氰基联苯-4-基)甲基]氨基}-3-硝基苯甲酸乙酯(SM1)为起始原料,以甲酸铵为供氢体,经催化转移氢化,还原得到3-氨基-2-[(2-氰基联苯-4-基)甲基]氨基苯甲酸乙酯(AQ-1),AQ-1与原碳酸四乙酯环化得到2-乙氧基-1-{[(2′-氰基联苯-4-基)甲基]苯并咪唑}-7-羧酸乙酯(AQ-2),AQ-2依次经过肟化、CDI环合和酯基水解,共计5步反应得到阿齐沙坦。结果目标产物结构经1H-NMR、13C-NMR、MS谱和元素分析确证,硝基还原反应收率由74.5%提高至90.6%。结论新工艺反应进程快、易操作,且有较好的反应选择性,避开了污染大、压力高等落后工艺,具有较高的商业化价值。 Objective To improve the nitro reduction process in the synthesis of azilsartan.Methods Using ethyl(2-ethoxy-1-benzimidazole)-7-carboxylate(SM1)as starting material,ethyl-3-amino-2-[(2′-cyanoiphenyl-4-yl)methyl]-amino benzoate(AQ-1)was synthesized by catalytic transfer hydrogenation with ammonium formate as hydrogen donor,followed by cyclization with tetraethyl orthocarbonate to obtain ethyl-2-ethoxy-1-[[(2′-cyanobiphenyl-4-yl)methyl]benzimidazole]-7-carboxylate(AQ-2).Finally,azilsartan(AQST)was synthesized by oximation,cyclization of CDI and ester hydrolysis.Results The structure of the product was verified by^1H-NMR/^(13)C-NMR/MS and elemental analysis.The yield of nitro reduction was increased from 74.5%to 90.6%.Conclusion The new process has the advantages of fast reaction,easy operation and good selectivity,which avoids heavy pollution and high pressure.The improved synthetic process has high industrialization prospect.
作者 王莹 郑爱华 蒋海婷 罗鹏 周海权 王栋 WANG Ying;ZHENG Aihua;JIANG Haiting;LUO Peng;ZHOU Haiquan;WANG Dong(Affiliated Huai'an Hospital of Xuzhou Medical University,Huai'an 223001,China;Administration of Work Safety of Huai An Industrial Park,Huai'an 223001,China;Jiangsu Runan Pharmaceutical CO.,Ltd.,Huai'an 223299,China)
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2023年第8期1005-1010,共6页 Journal of Shenyang Pharmaceutical University
关键词 阿齐沙坦 血管紧张素Ⅱ受体拮抗剂 甲酸铵 合成 azilsartan angiotension II receptor antagonist ammonium formate synthesis
  • 相关文献

参考文献6

二级参考文献30

  • 1周家成.甲酸铵及其他甲酸衍生物在药物合成中的应用[J].中国药科大学学报,1989,20(5):313-320. 被引量:5
  • 2李萍,王彤,刘玉超.常用抗高血压药的分类及应用[J].军医进修学院学报,2006,27(1):79-80. 被引量:6
  • 3吕卓人,黄若文,薛小临.2005年高血压领域中的热点问题[J].中国医刊,2006,41(8):5-7. 被引量:16
  • 4尹桂华.抗高血压药物的分类与合理使用[J].中国热带医学,2007,7(8):1400-1401. 被引量:11
  • 5Kohara Y,lmamiya E,Kubo K,et al.A new class of angiotensin Ⅱ receptor antagonists with a novel acidic bioisostere[J].Bioorg Med Chem Lett,1995,5 (17):1903-1908.
  • 6Kohara Y,Kubo K,Imamiya E,et al.Synthesis and angiotensin Ⅱ receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles asnovel tetrazole bioisosteres[J].J Med Chem,1996,39 (26):5228-5235.
  • 7仲建彦,稻田义行.杂环化合物,其制备及应用:中国,1067890[P].1993-01-13.
  • 8Kubo K,Kohara Y,Imamiya E,et al.Nonpeptide angiotensinⅡ receptor antagonists synthesis and biological activity of benzimidazolecarboxylic acids[J].J Med Chem,1993,36(15):2182-2195.
  • 9FDA. Pharmacology review [ EB/OL]. [2011 - 04 - 04 ]. http://www, accessdata, fda. gov/scripts/cder/drugsatfda/index. cfm? fuseaction = Search. Label ApprovaiHistory.
  • 10FDA. Clinical pharmacology biopharmaceutics review[ EB/OL]. FDA. [2011 -04 -04]. http://www, accessdata, fda. gov/ scripts/cder/drugsatfda/index, cfm? fuseaction = Search. Label_.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部